ATS 2024 Final Program

Click on the session title to view the speakers

94

SUNDAY • MAYs 19

Objectives At the conclusion of this session, the participant will be able to: • describe the circulation patterns of common respiratory viruses during the pandemic and their influence on SARS-CoV-2 susceptibility, as well as airway gene expression patterns that predispose to SARS-CoV-2 infection. • describe differential methylation patterns in nasal epithelia defining the endotype frequent asthma exacerbations in a pediatric cohort, and the potential role of the nervous system in the frequent exacerbator asthma phenotype. • define inverse relationships between T2 genes and antimicrobial genes in children with allergic asthma and rhinitis This session will highlight NIAID-funded programs utilizing airway omics to endotype lung diseases, including viral respiratory infection, exacerbation prone asthma and the relationship between allergic rhinitis and asthma. 12:00 Human Rhinoviruses Influence SARS-CoV-2 Infection Through Modulation of Airway Interferon Levels 12:20 Omics of the Asthma Frequent Exacerbator 12:40 Type-2 Inflammation Inversely Associates with Antimicrobial Immune Responses in the Airway Epithelium MD10 NIOSHOCCUPATIONAL RESPIRATORY DISEASE HEALTHHAZARD EVALUATIONS AND FIELD STUDIES 12:00 p.m. - 1:00 p.m. San Diego Convention Center Room 8 (Upper Level) Target Audience Providers of lung health, those interested in preventing occupational respiratory disease Objectives At the conclusion of this session, the participant will be able to: • counsel patients with work-related respiratory disease about whether and how to seek a NIOSH health hazard evaluation in their workplace. CDC - NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH MID-DAY SESSION

USDA MID-DAY SESSION

MD8 PULMONARY UPDATE FROM THE US FOOD AND DRUG ADMINISTRATION 12:00 p.m. - 1:00 p.m. San Diego Convention Center Room 6D (Upper Level) Target Audience Clinicians in practice, academic researchers, pharmacists, pharmaceutical representatives, international regulators Objectives At the conclusion of this session, the participant will be able to: • provide a better understanding of the regulatory considerations regarding chronic cough drug development programs • provide an update regarding regulatory considerations around drug development programs in fibrotic lung disease, e.g. IPF • provide an update of regulatory activities over the past year The most recent FDA actions, including recent drug approvals for pulmonary and critical care diseases, research endeavors, safety issues, and other hot topics that we have navigated over the past year in the Division of Pulmonology, Allergy, and Critical Care will be presented and discussed. 12:00 Regulatory Considerations for Chronic Cough Drug Development Programs 12:20 Regulatory Considerations for IPF Drug Development Programs 12:40 Hot Topics in the Division of Pulmonology, Allergy, and Critical Care 12:50 Question and Answer

NIAID MID-DAY SESSION

MD9 AIRWAY DISEASE ENDOTYPING USING OMICS 12:00 p.m. - 1:00 p.m.

San Diego Convention Center Room 29A-D (Upper Level)

Target Audience Clinicians, basic and clinical researchers

ATS 2024 Conference Program • San Diego, CA